264 related articles for article (PubMed ID: 26095743)
21. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
22. Effect of etanercept, infliximab and methotrexate in the treatment of arthritis.
Wang L; Liu Y; Su X; Liu S
Drug Res (Stuttg); 2015 Feb; 65(2):96-100. PubMed ID: 25050521
[TBL] [Abstract][Full Text] [Related]
23. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
24. Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.
Emery P; Vlahos B; Szczypa P; Thakur M; Jones HE; Woolcott J; Santos Estrella PV; Rolland C; Gibofsky A; Citera G; Sockalingam S; Marshall L
J Rheumatol; 2020 Apr; 47(4):493-501. PubMed ID: 31154413
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
27. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
28. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Shi R; Chen M; Litifu B
Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833
[TBL] [Abstract][Full Text] [Related]
29. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
Agnholt J; Dahlerup JF; Kaltoft K
Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
[TBL] [Abstract][Full Text] [Related]
31. Real-world retention rates of biologics in patients with rheumatoid arthritis.
Takami K; Tsuji S
Sci Rep; 2023 Dec; 13(1):21170. PubMed ID: 38040839
[TBL] [Abstract][Full Text] [Related]
32. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
33. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
Kristensen LE; Saxne T; Nilsson JA; Geborek P
Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
[TBL] [Abstract][Full Text] [Related]
34. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
35. [Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].
Song M; Li F; Xie X; Chen J; Tang M; Tian J; Du J; Ge Y; Li S; Xu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Sep; 43(9):982-986. PubMed ID: 30333289
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
[TBL] [Abstract][Full Text] [Related]
37. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
38. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
[TBL] [Abstract][Full Text] [Related]
39. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
[TBL] [Abstract][Full Text] [Related]
40. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?
Buch MH; Conaghan PG; Quinn MA; Bingham SJ; Veale D; Emery P
Ann Rheum Dis; 2004 Oct; 63(10):1344-6. PubMed ID: 15033655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
